Neopharm ** neol.pk ** amazing cancer drug pipeline

[mrvenue]

check out this new find
NEOPHARM
NEOL.pk

check out more details of the pipeline at
YouTube - NeoPharm: Laurence P. Birch, President and Chief Executive Officer

What I find amazing is the upside potential.

PREVIOUS blockbuster picks of mine:

ITMN
PCYC
LVS
MGM
F

[kion_yaar]

any upcoming news ?

[mrvenue]

During the past year we have continued to make solid progress with the development of our drug candidate portfolio and are extremely pleased to announce the results of our Phase II trials of LEP in recurrent breast cancer patients. The Phase II trial of LEP with 35 patients at a dose of 275 mg/m2 showed a response rate of 46% compared to 11% with free Taxol® and 22% with Abraxane®. While preparations are underway to start a Phase III trial of LEP, we are pleased to announce that we have started a second Phase II trial of LEP to enroll 35 additional patients to significantly increase the sample size to 70 patients.”

“We also are expecting to enroll patients in our Phase II clinical trial for the study of Liposome Entrapped Docetaxel (LE-DT), a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®, for locally advanced or metastatic pancreatic cancer patients. The Phase II trial of LE-DT will soon start enrolling patients for advanced prostate cancer patients,” commented Dr. Aquilur Rahman, President and Chief Executive Officer of NeoPharm. “We also recently announced the filing of an IND with the FDA for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF) which is the most deadly disease of the lungs in humans and for which there is currently no proven effective treatment. We expect to start a Phase I clinical trial for IPF in the second half of 2010.”

Cintredekin Besudotox, IL-13, for Idiopathic Pulmonary Fibrosis (IPF)

In December 2009, NeoPharm filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is the most deadly disease of the lungs in humans with very high morbidity, and there is currently no proven effective treatment for the cure of this disease. In the fourth quarter of 2009, the Company signed a letter of intent to enter into a clinical research agreement with Duke University, a non-profit educational and health care institution acting for and on behalf of its Duke Clinical Research Institute (“Duke”), regarding potential clinical trials with IL13-PE38 in patients with IPF. Upon submission of this IND, the FDA raised a few scientific and technical questions to which the Company is in the process of responding. The Company expects to begin enrolling patients in a Phase I clinical trial in the second half of 2010.